In an amicus brief filed Monday (Sept. 18) in the Merck case trying to stop Medicare drug negotiations, AARP argues American taxpayers support research on 99% of drugs and the negotiation program supports innovation while lowering drug prices. The nation’s largest seniors group counters an argument the pharmaceutical companies make in Merck & Co. v. HHS that allowing the government to negotiate Medicare drug prices will stifle innovation of new medicines. AARP says the industry argument sets up a...